• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

他汀不耐受——我们自以为无所不知，实则一无所知。

Statin Intolerance-We Know Everything, We Know Nothing.

作者信息

Banach Maciej

机构信息

Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), 93338 Lodz, Poland.

Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHRI), 93338 Lodz, Poland.

出版信息

J Clin Med. 2022 Sep 5;11(17):5250. doi: 10.3390/jcm11175250.

DOI:10.3390/jcm11175250
PMID:36079180
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9457222/
Abstract

Lipid disorders are the most common risk factors of cardiovascular disease (CVD) [...].

摘要

脂质紊乱是心血管疾病（CVD）最常见的危险因素[...]。

相似文献

1
Statin Intolerance-We Know Everything, We Know Nothing.他汀不耐受——我们自以为无所不知，实则一无所知。
J Clin Med. 2022 Sep 5;11(17):5250. doi: 10.3390/jcm11175250.
2
Adherence to statin therapy: it seems we know everything, yet we do nothing.他汀类药物治疗的依从性：似乎我们什么都知道，但却什么都没做。
Eur Heart J Open. 2022 Oct 26;2(6):oeac071. doi: 10.1093/ehjopen/oeac071. eCollection 2022 Nov.
3
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.他汀不耐受——统一定义的尝试。国际脂质专家小组立场文件。
Expert Opin Drug Saf. 2015 Jun;14(6):935-55. doi: 10.1517/14740338.2015.1039980. Epub 2015 Apr 24.
4
Clinicians learn less and less about more and more until they know nothing about everything; researchers learn more and more about less and less until they know everything about nothing: discuss.临床医生对越来越多的事物了解得越来越少，直到他们对任何事物都一无所知；研究人员对越来越少的事物了解得越来越多，直到他们对任何事物都了如指掌：讨论。
Behav Brain Sci. 2012 Oct;35(5):358-9. doi: 10.1017/S0140525X12001367.
5
A US Claims-Based Analysis of Real-World Lipid-Lowering Treatment Patterns in Patients With High Cardiovascular Disease Risk or a Previous Coronary Event.一项基于美国索赔数据的对高心血管疾病风险患者或既往有冠心病事件患者的真实世界降脂治疗模式分析。
Am J Cardiol. 2016 Feb 15;117(4):495-500. doi: 10.1016/j.amjcard.2015.11.035. Epub 2015 Dec 2.
6
Statin intolerance - a question of definition.他汀不耐受——定义问题。
Expert Opin Drug Saf. 2017 Jan;16(1):55-63. doi: 10.1080/14740338.2017.1238898. Epub 2016 Sep 27.
7
An assessment by the Statin Intolerance Panel: 2014 update.他汀不耐受评估小组报告：2014 年更新版
J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S72-81. doi: 10.1016/j.jacl.2014.03.002.
8
Statin Intolerance: the Clinician's Perspective.他汀不耐受：临床医生的观点
Curr Atheroscler Rep. 2015 Dec;17(12):69. doi: 10.1007/s11883-015-0552-3.
9
[Practical approach to statin intolerance].[他汀类药物不耐受的实用处理方法]
Vnitr Lek. 2015 Nov;61(11):936-41.
10
Expert opinion: the therapeutic challenges faced by statin intolerance.专家意见：他汀不耐受所面临的治疗挑战
Expert Opin Pharmacother. 2016 Aug;17(11):1497-507. doi: 10.1080/14656566.2016.1197202. Epub 2016 Jun 13.

本文引用的文献

1
Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).逐步诊断和管理他汀类药物相关肌肉症状患者的安慰剂/反安慰剂效应：国际脂质专家组（ILEP）的立场文件。
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1596-1622. doi: 10.1002/jcsm.12960. Epub 2022 Mar 10.
2
Influence of lipid-lowering drugs on inflammation: what is yet to be done?降脂药物对炎症的影响：尚待完成的工作有哪些？
Arch Med Sci. 2021 Mar 20;18(4):855-869. doi: 10.5114/aoms/133936. eCollection 2022.
3
Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE.在现实环境中，阿利西尤单抗治疗依从性及他汀类药物联合使用强度对其疗效和安全性的影响：ODYSSEY APPRISE研究结果
Arch Med Sci. 2021 Oct 29;18(2):285-292. doi: 10.5114/aoms/143476. eCollection 2022.
4
Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications.他汀类药物的副作用：从病理生理学到流行病学，再到诊断和治疗意义
Cardiovasc Res. 2023 Jan 18;118(17):3288-3304. doi: 10.1093/cvr/cvac020.
5
Prevalence of statin intolerance: a meta-analysis.他汀类药物不耐受的流行率：一项荟萃分析。
Eur Heart J. 2022 Sep 7;43(34):3213-3223. doi: 10.1093/eurheartj/ehac015.
6
PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.2021年波兰脂质紊乱诊断与治疗的PoLA/CFPiP/PCS/PSLD/PSD/PSH指南
Arch Med Sci. 2021 Nov 8;17(6):1447-1547. doi: 10.5114/aoms/141941. eCollection 2021.
7
A comprehensive review on the lipid and pleiotropic effects of pitavastatin.关于匹伐他汀的脂质及多效性作用的全面综述。
Prog Lipid Res. 2021 Nov;84:101127. doi: 10.1016/j.plipres.2021.101127. Epub 2021 Sep 9.
8
Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.降脂治疗在中欧和东欧的初级和二级保健中的应用：DA VINCI 观察性研究。
Atherosclerosis. 2021 Oct;334:66-75. doi: 10.1016/j.atherosclerosis.2021.08.035. Epub 2021 Aug 25.
9
Postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia.上市后营养警戒安全性概况：一类含红曲米的用于血脂异常的膳食食品补充剂。
Arch Med Sci. 2021 Mar 4;17(4):856-863. doi: 10.5114/aoms/133716. eCollection 2021.
10
Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations.他汀不耐受患者中的反安慰剂/安慰剂效应：制定建议的尝试。
Eur Heart J. 2021 Dec 14;42(47):4787-4788. doi: 10.1093/eurheartj/ehab358.